Physician profile
John C Puente
NPI 1194775916
$179,259.99
in general payments reported to CMS, 2019-2025
84 companies · $6,798 in 2025
The $6,798 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $28K · 2021: $34K · 2022: $41K · 2023: $19K · 2024: $8,792 · 2025: $6,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Consulting Fee: $10K · Travel and Lodging: $1,152 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,391.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,750.00 |
| Consulting Fee | $10,035.00 |
| Travel and Lodging | $1,152.35 |
| Education | $222.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $80,963.04 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Genzyme Corporation | $29,743.39 | 2019-2025 | |
| Genentech USA, INC. | $16,491.86 | 2019-2024 | Ocrevus |
| Celgene Corporation | $13,272.29 | 2019-2025 | Zeposia |
| Adamas Pharmaceuticals, INC. | $4,948.53 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $4,492.33 | 2020-2024 | Zeposia |
| Emd Serono, INC. | $4,106.32 | 2019-2025 | Mavenclad, Mavenclad |
| Livanova USA, INC. | $2,440.58 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Novartis Pharmaceuticals Corporation | $2,293.20 | 2019-2025 | |
| Pfizer INC. | $2,026.79 | 2019-2025 | |
| Abbvie INC. | $1,993.83 | 2019-2025 | |
| Mdd US Operations, LLC | $1,905.90 | 2020-2025 | Gocovri, Gocovri |
| Lilly USA, LLC | $1,242.10 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Amgen INC. | $1,160.85 | 2019-2024 | Aimovig, Uplizna |
| Teva Pharmaceuticals USA, INC. | $1,033.24 | 2020-2025 | Austedo Xr, Austedo, Austedo Xr |
Show all 80 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Puente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.